Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Current Ratio
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Regeneron Pharmaceuticals Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands


The current ratio exhibited considerable fluctuation between 2005 and 2025. Initially, the ratio demonstrated a strong upward trend, peaking in 2006 before experiencing a period of volatility and then generally stabilizing in the mid-3 to 5 range for much of the analyzed period.

Initial Growth & Subsequent Decline (2005-2009)
From 2005 to 2006, the current ratio increased from 8.46 to 10.44, indicating a strengthening short-term liquidity position. However, a significant decline followed, dropping to 2.81 by 2007. The ratio recovered somewhat in 2008 and 2009, reaching 6.23 and 4.55 respectively, but remained below the levels observed in the earlier years of the period.
Volatility & Stabilization (2010-2015)
The period between 2010 and 2015 was characterized by moderate fluctuations. The current ratio decreased from 3.28 in 2010 to a low of 2.56 in 2015. While there were year-to-year changes, the ratio generally remained within a relatively narrow band, suggesting a degree of stability in the company’s ability to cover its short-term obligations.
Recent Trends (2016-2025)
From 2016 onwards, the current ratio showed a renewed period of fluctuation. It increased to 3.82 in 2017, then decreased to 3.67 in 2019. A slight increase was observed in 2020 and 2021, reaching 3.63 and 3.56 respectively. The ratio then increased significantly to 5.06 in 2022 and 5.69 in 2023 before decreasing to 4.73 in 2024 and 4.13 in 2025. This recent pattern suggests a potential shift in liquidity management or changes in the composition of current assets and liabilities.
Overall Assessment
The observed trends indicate that the company’s short-term liquidity position has varied considerably over the analyzed timeframe. While generally maintaining a current ratio above 1.0, suggesting an ability to cover current liabilities with current assets, the fluctuations warrant further investigation. The increases in the later years of the period may be attributable to increased cash holdings or a decrease in current liabilities, while the declines could be due to increased short-term obligations or a reduction in liquid assets.

Comparison to Competitors

Regeneron Pharmaceuticals Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Regeneron Pharmaceuticals Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)